BACKGROUND: The largest known outbreak of enterovirus D68 (EV-D68) infections occurred during 2014. The goal of our study is to characterize the illness severity and clinical presentation of children infected with EV-D68 in comparison to non-EV-D68-human rhinoviruses/enteroviruses (HRV/EV). METHOD: Our study is a retrospective analysis of severity level, charges and length of stay of children who presented to St. Louis Children's Hospital from August 8, 2014 to October 31, 2014 and tested positive for EV-D68 in comparison to non-EV-D68-HRV/EV-infected patients. Chart review was performed for all EV-D68-infected patients and age and severity matched non-EV-D68-HRV/EV-infected patients. RESULT: There was a striking increase in hospital census in August of 2014 in our hospital with simultaneous increase in the number of patients with EV-D68 infection. There was no significant difference in severity of illness, length of stay or total charges between EV-D68-infected and non-EV-D68-HRV/EV-infected children. EV-D68 infection was characterized by presenting complaints of difficulty breathing (80%) and wheezing (67%) and by findings of tachypnea (65%), wheezing (71%) and retractions (65%) on examination. The most common interventions were albuterol (79%) and corticosteroid (68%) treatments, and the most common discharge diagnosis was asthma exacerbation (55%). CONCLUSION: EV-D68 caused a significant outbreak in 2014 with increased hospital admissions and associated increased charges. There was no significant difference in severity of illness caused by EV-D68 compared with non-EV-D68-HRV/EV infections suggesting that the impact from EV-D68 was because of increased number of infected children presenting to the hospital and not necessarily due to increased severity of illness.
BACKGROUND: The largest known outbreak of enterovirus D68 (EV-D68) infections occurred during 2014. The goal of our study is to characterize the illness severity and clinical presentation of children infected with EV-D68 in comparison to non-EV-D68-human rhinoviruses/enteroviruses (HRV/EV). METHOD: Our study is a retrospective analysis of severity level, charges and length of stay of children who presented to St. Louis Children's Hospital from August 8, 2014 to October 31, 2014 and tested positive for EV-D68 in comparison to non-EV-D68-HRV/EV-infectedpatients. Chart review was performed for all EV-D68-infectedpatients and age and severity matched non-EV-D68-HRV/EV-infectedpatients. RESULT: There was a striking increase in hospital census in August of 2014 in our hospital with simultaneous increase in the number of patients with EV-D68 infection. There was no significant difference in severity of illness, length of stay or total charges between EV-D68-infected and non-EV-D68-HRV/EV-infectedchildren. EV-D68 infection was characterized by presenting complaints of difficulty breathing (80%) and wheezing (67%) and by findings of tachypnea (65%), wheezing (71%) and retractions (65%) on examination. The most common interventions were albuterol (79%) and corticosteroid (68%) treatments, and the most common discharge diagnosis was asthma exacerbation (55%). CONCLUSION:EV-D68 caused a significant outbreak in 2014 with increased hospital admissions and associated increased charges. There was no significant difference in severity of illness caused by EV-D68 compared with non-EV-D68-HRV/EV infections suggesting that the impact from EV-D68 was because of increased number of infected children presenting to the hospital and not necessarily due to increased severity of illness.
Authors: Alexander L Greninger; Samia N Naccache; Kevin Messacar; Anna Clayton; Guixia Yu; Sneha Somasekar; Scot Federman; Doug Stryke; Christopher Anderson; Shigeo Yagi; Sharon Messenger; Debra Wadford; Dongxiang Xia; James P Watt; Keith Van Haren; Samuel R Dominguez; Carol Glaser; Grace Aldrovandi; Charles Y Chiu Journal: Lancet Infect Dis Date: 2015-03-31 Impact factor: 25.071
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Todd F Hatchette; Steven J Drews; Elsie Grudeski; Tim Booth; Christine Martineau; Kerry Dust; Richard Garceau; Jonathan Gubbay; Tim Karnauchow; Mel Krajden; Paul N Levett; Tony Mazzulli; Ryan R McDonald; Alan McNabb; Samira Mubareka; Robert Needle; Astrid Petrich; Susan Richardson; Candy Rutherford; Marek Smieja; Raymond Tellier; Graham Tipples; Jason J LeBlanc Journal: J Clin Microbiol Date: 2015-03-04 Impact factor: 5.948
Authors: Christopher M Oermann; Jennifer E Schuster; Gregory P Conners; Jason G Newland; Rangaraj Selvarangan; Mary Anne Jackson Journal: Ann Am Thorac Soc Date: 2015-05
Authors: Randy Poelman; Isabelle Schuffenecker; Coretta Van Leer-Buter; Laurence Josset; Hubert G M Niesters; Bruno Lina Journal: J Clin Virol Date: 2015-07-26 Impact factor: 3.168
Authors: Kristine M Wylie; Todd N Wylie; Anthony Orvedahl; Richard S Buller; Brandi N Herter; Vincent Magrini; Richard K Wilson; Gregory A Storch Journal: Emerg Infect Dis Date: 2015-01 Impact factor: 6.883
Authors: Charles B Foster; Ritika Coelho; Paul M Brown; Aman Wadhwa; Amena Dossul; Blanca E Gonzalez; Silvia Cardenas; Camille Sabella; Debbie Kohn; Sherilynn Vogel; Belinda Yen-Lieberman; Giovanni Piedimonte Journal: Pediatr Pulmonol Date: 2017-01-30
Authors: Timothy J Savage; Jane Kuypers; Helen Y Chu; Miranda C Bradford; Anne Marie Buccat; Xuan Qin; Eileen J Klein; Keith R Jerome; Janet A Englund; Alpana Waghmare Journal: Influenza Other Respir Viruses Date: 2018-03-23 Impact factor: 4.380